Get started
Author

Sara Muhammad El-Hanboshy

Observed name: El-Hanboshy, Sara Muhammad
Observed institution: Damanhour University
ORCID: 0000-0003-2389-4468
Observed ORCID: 0000-0003-2389-4468
OpenAlex ID: A5084799874
Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways
2021 · Sara Muhammad El-Hanboshy, Maged Wasfy Helmy, et al. · Molecular Biology Reports · 32
Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · Sara Muhammad El-Hanboshy, Ihab T. Abdel-Raheem, et al. · Future Journal of Pharmaceutical Sciences · 1
PDF
Additional file 6 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 1 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 7 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 5 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 2 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 3 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 8 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Additional file 4 of Repurposing baricitinib and/or rosuvastatin to reinvigorate the anticancer immune response via suppressing PD-1/PD-L1 and CTLA-4 inhibitory immune checkpoints and correlated oncogenic pathways in lung cancer models
2026 · El-Hanboshy, Sara Muhammad, Abdel-Raheem, Ihab T., et al. · Figshare
Works count: 11
Citation count: 33
H-index: 1
I10-index: 1
Year
Topic
Type